In This Article:
-
NAV per Share: Down 5.2% in the half-year, impacted by quoted holdings.
-
Life Science Portfolio Value: Decreased by 8.8% in the half-year.
-
Capital Deployment: GBP90 million deployed into the life science portfolio.
-
Uplift from Private Financings: GBP25 million.
-
Share Buyback Commitment: Further GBP15 million committed.
-
Capital Pool: GBP352.7 million at the end of September.
-
Capital Raised: GBP305.6 million in the period, with GBP170.5 million from third-party investors.
-
Capital Deployment Guidance: GBP150 million to GBP200 million for the year.
Release Date: November 14, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Syncona Ltd (LSE:SYNC) has successfully rebalanced its portfolio towards late-stage clinical companies, which are hitting key value inflection points.
-
The company has attracted significant third-party capital for its portfolio companies, evidencing the quality and potential of its investments.
-
Autolus, a portfolio company, received approval for its novel CAR T-cell therapy, marking a significant achievement in the biotech sector.
-
Syncona Ltd (LSE:SYNC) has committed an additional GBP15 million to a share buyback, demonstrating confidence in its portfolio and future prospects.
-
The company has largely completed building its team, including the appointment of Ken Galbraith as Chair of SIML, enhancing its leadership strength.
Negative Points
-
Net Asset Value (NAV) per share decreased by 5.2% in the half-year, primarily due to underperformance in quoted holdings.
-
The life science portfolio value declined by 8.8% during the period, reflecting challenges in the biotech market.
-
Autolus' share price declined by 43% over the period, highlighting the volatility in biotech stocks.
-
The company faced capital-intensive challenges and delays in manufacturing cell therapies, impacting returns.
-
Despite improvements, the financing markets remain challenging, affecting capital access for biotech companies.
Q & A Highlights
Q: What makes the PI3K delta inhibitor from iOnctura exciting, given the historical challenges with this class of drugs? A: Roel Bulthuis, Managing Partner, explained that the iOnctura molecule was developed to be a safe modulator of PI3K delta, focusing on avoiding the toxic effects seen in previous inhibitors. John Tsai, Executive Partner, added that the allosteric modulation of the drug avoids off-target effects, leading to a better safety profile and efficacy, particularly in uveal melanoma, where there is significant unmet need.